北海道大学病院は、札幌市北区にある北海道大学の大学病院。通称北大病院。北海道大学医学部・歯学部附属の教育・研究施設であり、医科・歯科の高度な医療を提供する北海道を代表する医療施設になっている。

During the past decade, Hokkaido University Hospital conducted 189 clinical trials. In the 10-year time frame, 189 clinical trials started and 82 clinical trials were completed, i.e. on average, 43.4% percent of trials that started reached the finish line to date. In the past 5 years, 87 clinical trials started and 58 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hokkaido University Hospital" #1 sponsor was "Pfizer" with 22 trials, followed by "Hoffmann-La Roche" with 15 trials sponsored, "Janssen Research & Development, LLC" with 15 trials sponsored, "Loxo Oncology, Inc." with 10 trials sponsored and "Boehringer Ingelheim" with 10 trials sponsored. Other sponsors include 163 different institutions and companies that sponsored additional 90 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hokkaido University Hospital" #1 collaborator was "Eli Lilly and Company" with 11 trials as a collaborator, "National Cancer Institute (NCI)" with 8 trials as a collaborator, "Merck Sharp & Dohme LLC" with 5 trials as a collaborator, "NRG Oncology" with 5 trials as a collaborator and "AstraZeneca" with 4 trials as a collaborator. Other collaborators include 73 different institutions and companies that were collaborators in the rest 63 trials.

According to Clinical.Site data, the most researched conditions in "Hokkaido University Hospital" are "Gastric Cancer" (6 trials), "Rheumatoid Arthritis" (6 trials), "Systemic Lupus Erythematosus" (6 trials), "Chronic Lymphocytic Leukemia" (5 trials) and "Multiple Myeloma" (5 trials). Many other conditions were trialed in "Hokkaido University Hospital" in a lesser frequency.

Most popular intervention types in "Hokkaido University Hospital" are "Drug" (207 trials), "Other" (30 trials), "Biological" (24 trials), "Procedure" (10 trials) and "Radiation" (7 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (52 trials), "Cisplatin" (10 trials), "Carboplatin" (9 trials), "Paclitaxel" (9 trials) and "Rituximab" (7 trials). Other intervention names were less common.

The vast majority of trials in "Hokkaido University Hospital" are 206 trials for "All" genders, 24 trials for "Female" genders and 7 trials for "Male" genders.

Currently, there are NaN active trials in "Hokkaido University Hospital". undefined are not yet recruiting, 53 are recruiting, 61 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 104 completed trials in Hokkaido University Hospital, 1 suspended trials, and 12 terminated clinical trials to date.

Out of the total trials that were conducted in Hokkaido University Hospital, 21 "Phase 1" clinical trials were conducted, 80 "Phase 2" clinical trials and 141 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 4 trials that are defined as “Not Applicable".

Hokkaido University Hospital has several departments that took part in Clinical trials: "Hokkaido Cancer Center" - 2 trials